Smartlab Europe

Alto Pharma to introduce DermSafe hand sanitizer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...
- Advertisement -

Alto Pharmaceuticals is set to introduce Skinvisible Pharmaceuticals’ DermSafe antimicrobial hand sanitizer in Canada on 1 September 2011.Under an agreement signed between both the companies, Skinvisible has given Canadian marketing rights of DermSafe to Alto. Alto expects to market the product under the name DermSafePC.DermSafe is made with 4% chlorhexidine gluconate and it does not contain delivers protection in a lotion formulation that defends the skin from outside irritants.Skinvisible president and CEO Terry Howlett said they believe that the introduction of DermSafePC will help generate a very positive response from end-users as well as potential licensees worldwide.

“The manufacturing of DermSafe in Canada is critical to Skinvisible as it will facilitate the quick introduction of the product in Europe and Singapore, where DermSafe is already approved for importation,” Howlett said.

Latest stories

Related stories

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »